Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)

Summary by Charleston Gazette-Mail
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute…

80 Articles

Fox 4 Kansas CityFox 4 Kansas City
+77 Reposted by 77 other sources
Center

Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)

·Kansas City, United States
Read Full Article
targetedonc.comtargetedonc.com

Ligufalimab Earns FDA Orphan Drug Designation in AML

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic malignancies and solid tumors.

Read Full Article
FinnoexpertFinnoexpert

Akeso’s cancer therapy gets orphan status from US FDA - Finnoexpert

Akeso’s cancer therapy gets orphan status from US FDA Source link

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 63% of the sources are Center
63% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Fox 4 Kansas City broke the news in Kansas City, United States on Monday, September 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Hong Kong City icon

Hong Kong City

News
For You
SearchBlindspotLocal